Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Apolipoprotein B

Lipids

ApoBApolipoprotein B-100

Review status

Currently under review

Pending specialist review and validation.

What it shows

Apolipoprotein B is the main structural protein on LDL particles and other cholesterol- and triglyceride-carrying lipoproteins that can contribute to plaque buildup in arteries. The ApoB test measures the concentration of this protein in your blood, which reflects the number of atherogenic particles rather than just the amount of cholesterol inside them.

It complements a standard lipid panel and can provide a clearer picture of particle-related risk when triglycerides are elevated or cholesterol results seem mismatched with clinical risk.

Why it matters

ApoB helps estimate your burden of particles that can enter artery walls and drive atherosclerosis. Clinicians use it to refine cardiovascular risk assessment, especially if you have diabetes, metabolic syndrome, chronic kidney disease, suspected familial lipid disorders, or persistently high triglycerides.

It is also used to monitor how well treatments like statins, ezetimibe, or PCSK9 inhibitors are lowering atherogenic particles. In some cases, ApoB adds information beyond LDL cholesterol and can guide the intensity of lifestyle and medication strategies.

Understanding your results

Your ApoB result is interpreted alongside your lipid panel, personal risk factors, and treatment goals. A higher value suggests more atherogenic particles and may prompt attention to diet, physical activity, weight management, and medication adjustments.

A lower than expected value can be seen with certain genetic conditions or illnesses and should be interpreted in clinical context. If results do not match your overall risk or symptoms, your clinician may repeat testing, evaluate secondary causes such as thyroid or liver conditions, and tailor therapy to your individualized cardiovascular risk.

Reference ranges

00.8 g/L
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Apolipoprotein B

  • Fasting and sample handling

    ApoB is relatively stable with or without fasting, but some labs prefer consistent collection conditions. Hemolysis, prolonged tourniquet time, or delayed processing can affect results, so proper phlebotomy and prompt handling matter.

  • Metabolic and endocrine conditions

    Obesity, insulin resistance, type 2 diabetes, and hypothyroidism often raise atherogenic particles and can increase ApoB. Hyperthyroidism, severe liver disease, or malabsorption may lower ApoB; addressing these conditions helps interpret results.

  • Medications and supplements

    Statins, ezetimibe, PCSK9 inhibitors, and fibrates generally lower ApoB. Some drugs, such as anabolic steroids, progestins, or isotretinoin, can raise atherogenic particles. Always tell your clinician about prescriptions and over-the-counter products.

  • Pregnancy and hormonal changes

    Lipid levels and ApoB typically rise during pregnancy, especially later in gestation, reflecting physiologic changes. Hormonal therapies, including some contraceptives, may also shift lipoprotein patterns and influence ApoB.

  • Genetic lipid disorders

    Familial hypercholesterolemia and familial combined hyperlipidemia often show elevated ApoB, while familial hypobetalipoproteinemia can show low values. Family history and genetic testing can clarify the cause when results are unexpected.

  • Lifestyle factors

    Dietary patterns high in refined carbohydrates, smoking, heavy alcohol use, and inactivity can raise atherogenic particles over time. Heart-healthy eating, regular exercise, weight management, and tobacco cessation support favorable ApoB levels.

2026

References

  1. McGill University Health Centre. (2015, March 15). Apolipoprotein B (Task CD 657733). Laboratory reference ranges.
  2. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., & Peralta, C. A. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625 External link
  3. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M.-R., Tokgozoglu, L., & Wiklund, O. (2019). 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455 External link